Xanthine oxidase inhibitors and methods of use

A method for treating a condition, mediated at least in part by xanthine oxidase, in a patient in need thereof, comprising administering to the patient an effective amount of a compound-of Formula III:

• or a tautomer, a pharmaceutically acceptable salt and/or solvate thereof,
• where X and Y are independently selected from the group consisting of —OR3, —SR3, —NHR3, and —NHOR3 or X and Y are joined together to form ═O, ═S, ═NR3, ═NOR3 or a cyclic ring system of the formula:
• where X1 and Y1 are independently selected from the group consisting of —O—, —S—, —SO2—, and —N(R3)—, and L is —C(O)—or C2 to C4 alkylene group optionally substituted with one or two oxo;
• and
• each R20 is independently selected from the group consisting of hydrogen, —C(═O)R4, —C(═O)NHR4, —C(═S)R4, —C(═S)NHR4, —C(═O)OR4, —C(═O)SR4, —C(═S)OR4, —P(═O)R4, —P(═O)2R4, —P(═O)NHR4, —P(═O)2NHR4, —P(═S)NHR4, —P(═O)OR4, —P(═O)2OR4, —P(═O)SR4, —P(═O)2SR4, and —P(═S)OR4, wherein R4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C7 cycloalkyl, C2-C6 alkenyl, C4-C7 cycloalkenyl, C2-C6 alkynyl, C6-C10 aryl, and C5-C6 heteoaryl or heterocycle having 1 to 3 heteroatoms selected from O, S, SO2, N, NR11, and R30;
• or —OR4 is a hydroxy group esterified with a phospholipid;
• where R11 is hydrogen or C1 to C6 alkyl, or C5-C6 heteroaryl having 1 to 3 heteroatoms selected from O, S, SO2, N, and NR12;
• R12 is hydrogen or C1 to C6 alkyl;
• and R30 is a saturated fatty chain or an unsaturated fatty chain.

A method for treating hyperuricemia in a patient in need thereof, comprising administering to the patient an effective amount of a compound of Formula III:

• or a tautomer, a pharmaceutically acceptable salt and/or solvate thereof, where X and Y are independently selected from the group consisting of —OR3, —SR3, —NHR3, and —NHOR3 or X and Y are joined together to form ═O, ═S, ═NR3, ═NOR3 or a cyclic ring system of the formula:
• where X1 and Y1 are independently selected from the group consisting of —O—, —S—, —SO2—, and —N(R3)—, and L is —C(O)—or C2 to C4 alkylene group optionally substituted with one or two oxo;
• and
• each R20 is independently selected from the group consisting of hydrogen, —C(═O)R4, —C(═O)NHR4, —C(═S)R4, —C(═S)NHR4, —C(═O)OR4, —C(═O)SR4, —C(═S)OR4, —P(═O)R4, —P(═O)2R4, —P(═O)NHR4, —P(═O)2NHR4, —P(═S)NHR4, —P(═O)OR4, —P(═O)2OR4, —P(═O)SR4, —P(═O)2SR4, and —P(═S)OR4, wherein R4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C7 cycloalkyl, C2-C6 alkenyl, C4-C7 cycloalkenyl, C2-C6 alkynyl, C6-C10 aryl, and C5-C6 heteoaryl or heterocycle having 1 to 3 heteroatoms selected from O, S, SO2, N, NR11, and R30 ;
• or —OR is a hydroxy group esterified with a phospholipid;
• where R11 is hydrogen or C1 to C6 alkyl, or C5-C6 heteroaryl having 1 to 3 heteroatoms selected from O, S, SO2, N, and NR12;
• R12 is hydrogen or C1 to C6 alkyl;
• and R30 is a saturated fatty chain or an unsaturated fatty chain.